Deaths Not Caused by H1N1 Vaccine, Says World Health Organization
The U.N. agency reaffirmed that the pandemic vaccine was safe and voiced concern that some pregnant women and others at risk were shunning it because of a fear of side effects.
“No new safety issue has been identified from reports issued to date … Reporting so far reconfirms that the pandemic flu vaccine is as safe as the seasonal flu vaccine,” Marie-Paule Kieny, WHO’s top vaccine expert, told a telephone conference.
Governments have so far reported that 65 million vaccine doses have been administered against H1N1, known as swine flu, in 16 countries, but the true figure is probably higher since immunization campaigns are under way in 40 countries, she said.
Side effects commonly reported include swelling and redness or pain at the injection site, although some had fever or headache, and all symptoms usually disappear after 48 hours.
A “small number of deaths” had been reported, she said, and a WHO spokeswoman later put the figure at 41 in six countries.
“Although some investigations are still ongoing, the results of the completed investigations reported to WHO have ruled out that the pandemic vaccine is the cause of death,” Kieny said.
Fewer than a dozen suspected cases of Guillain-Barre syndrome have been reported following pandemic vaccination, she said. “Only a few of this Guillain-Barre may be linked to the pandemic vaccine….and patients have recovered,” she added.
The rare neurological condition was linked to a 1976 U.S. swine flu vaccination campaign. Although no case of Guillain-Barre syndrome was ever linked to the vaccine, a belief that the vaccine was worse than the illness remains widespread.
“NO SIGNIFICANT DIFFERENCE”
GlaxoSmithKline Plc, AstraZeneca Plc, Novartis and Sanofi-Aventis are among about 25 manufacturers producing H1N1 vaccine using different techniques.
“No significant difference in the safety profile between different types of vaccine has been detected,” Kieny said.
She denounced conspiracy theories about vaccines circulating on the Internet, saying they were causing “artificial worries”.
“We have to reiterate that the vaccines are safe, that the disease in certain people can be severe and can be cause of death,” she said.
Novartis said on Tuesday a U.S. clinical study suggested just half a dose of its H1N1 vaccine might be enough to generate a protective immune response.
Kieny said the WHO was aware of reports from other drug makers that half a dose was effective, but cautioned that the studies usually involved limited numbers of people.
“It may well be the case that a smaller quantity of vaccine may be protective, but it is really up to national regulators to define what is the best regimen for immunization in their countries,” she said. “Currently, we think that one dose of a licensed vaccine is what should be used in adults at least.”
A survey of doctors showed on Wednesday that more than half of Britons being offered vaccination against H1N1 were turning it down because they feared side effects or believed the virus was too mild to bother.
“It is worrying indeed that certain groups don’t seem to be coming readily to be vaccinated. But we hope that the data … on the safety of these vaccines will dissipate the worries that a population might have and will help convince them that the vaccine is safe and vaccination will protect them against this disease which can be severe,” Kieny said.
(Additional reporting by Jonathan Lynn; Editing by Sam Cage and Andrew Dobbie)
- TikTok Must Face Lawsuit Over 10-Year-Old Girl’s Death, Appeals Court Rules
- Mailing a Letter, in Context With Other Clues, Is Sufficient Cancellation – NC High Court
- The Murdaugh Drama in SC Continues: Store That Sold Beer Now Suing its Insurers
- Insurtech Root, Goosehead Partner on Tech Integration for Independent Agents